Granted Patent
B2
US 12,553,894 · App. 18/212,606 · Granted Feb 17, 2026
Methods and kits for quantifying the removal of mock virus particles from a purified solution
Assignee:
Cygnus Technologies, LLC
G01N33/56983A61K39/12A61K39/23A61J1/00A61K39/21A61K2039/5258C12N2740/10023C12N2750/14023C12Q1/701C12Q2600/158G01N2333/015G01N2333/15
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
Claims (4)
1 . A kit comprising a Mouse Minute Virus (MMV) Mock Viral Particle (MVP) stock solution comprising a modified MMV MVP, wherein the MMV MVP is a non-infectious, non-replicating assembled unit comprising a MMV VP2 viral capsid protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 6, wherein the stock solution comprises at least 1×10 7 MMV MVP/ml of the MMV MVP, and wherein non-MMV MVP proteins are less than 5% of all proteins in the stock solution.
2 . The kit of claim 1 , wherein the MMV MVP does not comprise a MMV VP1 viral capsid protein.
3 . The kit of claim 1 , wherein the MMV VP2 viral capsid protein is encoded by a nucleic acid comprising SEQ ID NO: 5.
4 . The kit of claim 1 , wherein the MMV VP2 capsid protein comprises SEQ ID NO: 6.
Assignments (3)
SECURITY INTEREST
Recorded Jun 3, 2026
From: TRILINK BIOTECHNOLOGIES, LLC; CYGNUS TECHNOLOGIES, LLC; GLEN RESEARCH, LLC
To: BSP AGENCY, LLC, AS COLLATERAL AGENT
Reel/Frame 074835/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 17, 2024
From: MOCKV SOLUTIONS LLC
To: CYGNUS TECHNOLOGIES, LLC
Reel/Frame 069609/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 20, 2023
From: CETLIN, DAVID; DHAR, ARUN
To: MOCKV SOLUTIONS LLC
Reel/Frame 064972/0383 →
Continuity (5)
Provisional Application
61875729
· Sep 10, 2013
References Cited (90)
US 5173399A
· Mehta et al.
· 1992
[cited by applicant]
US 5714316A
· Weiner et al.
· 1998
[cited by applicant]
US 5814442A
· Natarajan et al.
· 1998
[cited by applicant]
US 5827647A
· Young
· 1998
[cited by examiner]
US 5905040A
· Mazzara et al.
· 1999
[cited by applicant]
US 7763260B2
· Virgin
· 2010
[cited by applicant]
US 9632087B2
· Cetlin et al.
· 2017
[cited by applicant]
US 20030108864A1
· Liu et al.
· 2003
[cited by applicant]
US 20030129744A1
· Schlapp et al.
· 2003
[cited by applicant]
US 20040002058A1
· Cosenza
· 2004
[cited by applicant]
US 20060281128A1
· Lu et al.
· 2006
[cited by applicant]
US 20070184068A1
· Renner et al.
· 2007
[cited by applicant]
US 20080132688A1
· Zhou
· 2008
[cited by applicant]
US 20100136025A1
· Hickman et al.
· 2010
[cited by applicant]
US 20100297604A1
· Li et al.
· 2010
[cited by applicant]
US 20110177539A1
· Sutton et al.
· 2011
[cited by applicant]
US 20110243986A1
· Deng et al.
· 2011
[cited by applicant]
US 20120088228A1
· Asher et al.
· 2012
[cited by applicant]
US 20130273109A1
· Settembre et al.
· 2013
[cited by applicant]
US 20150072339A1
· Cetlin et al.
· 2015
[cited by applicant]
JP 2011512151A
· 2011
[cited by applicant]
Livingston, R. S., et al., Sep. 2002, Serodiagnosis of Mice Minute Virus and Mouse Parvovirus Infections in Mice by Enzyme-Linked Immunosorbent Assay with Baculovirus-Expressed Recombinant VP2 Proteins, Clin. Diag. Lab.…
[cited by examiner]
Astell, C. R., et al., Feb. 1986, DNA Sequence of the Lymphotropic Variant of Minute Virus of Mice, MVM(i), and Comparison with the DNA Sequence oof the Fibrotropic Prototype Strain, J. Virol. 57(2):656-669.
[cited by examiner]
Farr, G. A.., and P. Tattersall, 2004, A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection, Virol. 323:243-256.
[cited by examiner]
Reguera, J., et al., May 2005, Functional Relevance of Amino Acid Residues Involved in Interactions with Ordered Nucleic Acid in a Spherical Virus, J. Biol. Chem. 280(18):17969-17977.
[cited by examiner]
D'Abramo Jr., A. M., et al., 2005, Host range mutants of Minute Virus of Mice with a single VP2 amino acid change require additional silent mutations that regulate NS2 accumulation, Virol. 340:143-154.
[cited by examiner]
Carreira, A., et al., Feb. 2004, In Vitro Disassembly of a Parvovirus Capsid and Effect on Capsid Stability of Heterologous Peptide Insertions in Surface Loops, J. Biol. Chem. 279(8):6517-6525.
[cited by examiner]
Sela-Culang, I., et al., Oct. 2013, The structural basis of antibody-antigen recognition, Front. Immunol. 4, Article 302, pp. 1-13.
[cited by examiner]
“GenBank Accession No. X02481.1”, National Center for Biotechnology Information, Jul. 26, 2016, 5 pages.
[cited by applicant]
“Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products”, EMEA European Medicines Agency , Jul. 2008, pp. 1-9.
[cited by applicant]
“ICH Topic Q 5 A (R1) Note for Guidance on Quality of Biotechnology Products, Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin”, EMEA European Medicines Agency, CPMP/IC…
[cited by applicant]
“Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses”, EMEA The European Agency for the Evaluation of Medicinal Produc…
[cited by applicant]
“Process Validation in Manufacturing of Biopharmaceuticals”, 3rd Edition, Biotechnology and Bioprocessing Series, vol. 35, Chapter 1, May 11, 2012, 8 pages.
[cited by applicant]
“Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin Q5A(R1)”, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for …
[cited by applicant]
U.S. Appl. No. 16/386,327, “Final Office Action”, Sep. 28, 2022, 12 pages.
[cited by applicant]
U.S. Appl. No. 16/386,327, “Final Office Action”, Jun. 10, 2021, 12 pages.
[cited by applicant]
U.S. Appl. No. 16/386,327, “Non-Final Office Action”, Dec. 22, 2021, 11 pages.
[cited by applicant]
U.S. Appl. No. 16/386,327, “Non-Final Office Action”, Sep. 3, 2021, 12 pages.
[cited by applicant]
U.S. Appl. No. 16/386,327, “Notice of Allowance”, Mar. 28, 2023, 11 pages.
[cited by applicant]
U.S. Appl. No. 16/386,327, “Supplemental Notice of Allowability”, Apr. 17, 2023, 5 pages.
[cited by applicant]
Adler, et al., “Novel Strategies and Tools for Enhanced Sensitivity in Routine Biomolecule Analytics”, Current Pharmaceutical Analysis, vol. 5, No. 4, Nov. 2009, pp. 390-407.
[cited by applicant]
Andersson, et al., “Validation Study for the Removal/Inactivation of Viruses During a Chromatographic Purification Process for Albumin and IgG”, Presentation at the 24th Conference of the International Society of Blood …
[cited by applicant]
Aranha, et al., “Viral Clearance Strategies for Biopharmaceutical Safety—Part II: A Multifaceted Approach to Process Validation”, Pharmaceutical Technology, Biotech Trends, vol. 25, No. 6, Jun. 2001, pp. 26-42.
[cited by applicant]
Aranha, et al., “Virus Safety of Biopharmaceuticals: Absence of Evidence is Not Evidence of Absence”, Contract Pharma, 2011, pp. 82-87.
[cited by applicant]
AU2014320015, “First Examination Report”, Oct. 31, 2019 , 4 pages.
[cited by applicant]
AU2021200484, “First Examination Report”, Jul. 19, 2022, 5 pages.
[cited by applicant]
Burnouf, et al., “Place of Nanofiltration for Assuring Viral Safety of Biologicals”, Current Nanoscience, vol. 1, No. 3, Nov. 2005, pp. 189-201.
[cited by applicant]
Caballero, et al., “Rotavirus Virus-Like Particles as Surrogates in Environmental Persistence and Inactivation Studies”, Applied and Environmental Microbiology, vol. 70, No. 7, Jul. 2004, pp. 3904-3909.
[cited by applicant]
Cipriano, et al., “Effectiveness of Various Processing Steps for Viral Clearance of Therapeutic Proteins: Database Analyses of Commonly Used Steps”, Methods in Molecular Biology, vol. 899, Jan. 2012, pp. 277-292.
[cited by applicant]
Connell-Crowley, et al., “Using High Throughput Screening to Define Virus Clearance by Chromatography Resins”, Biotechnology and Bioengineering, vol. 110. No. 7, Jul. 2013, pp. 1984-1994.
[cited by applicant]
Curtis, et al., “Generic/Matrix Evaluation of SV40 Clearance by Anion Exchange Chromatography in Flow-Through Mode”, Biotechnology and Bioengineering, vol. 84, No. 2, Oct. 20, 2003, pp. 179-186.
[cited by applicant]
Darling, “Validation of Biopharmaceutical Purification Processes for Virus Clearance Evaluation”, Molecular Biotechnology, vol. 21, No. 1, May 2002, pp. 57-83.
[cited by applicant]
De Wit, “Real-Time Quantitative PCR for Retrovirus-Like Particle Quantification in CHO Cell Culture”, Biologicals, vol. 28, No. 3, Sep. 2000, pp. 137-148.
[cited by applicant]
EP14843784.1, “Extended European Search Report”, Mar. 28, 2017, 8 pages.
[cited by applicant]
Grasso, et al., “Viral Nanoparticles as Macromolecular Devices for New Therapeutic and Pharmaceutical Approaches”, International Journal of Physiology, Pathophysiology and Pharmacology, vol. 2, No. 2, Jul. 6, 2010, pp. …
[cited by applicant]
Grgacie, et al., “Virus-Like Particles: Passport to Immune Recognition”, Methods, vol. 40, No. 1, Sep. 2006, pp. 60-65.
[cited by applicant]
Grimm, et al., “Titration of AAV-2 Particles via a Novel Capsid Elisa: Packaging of Genomes Can Limit Production of Recombinant AAV-2”, Gene therapy, vol. 6, No. 7, Jul. 1999, pp. 1322-1330.
[cited by applicant]
Hendrickson, et al., “High Sensitivity Multianalyte Immunoassay Using Covalent DNA-Labeled Antibodies and Polymerase Chain Reaction”, Nucleic Acids Research, vol. 23, No. 3, Feb. 11, 1995, pp. 522-529.
[cited by applicant]
Henzler, et al., “Avoiding Viral Contamination in Biotechnological and Pharmaceutical Processes”, Nature Biotechnology, vol. 16, No. 11, Nov. 1998, pp. 1077-1079.
[cited by applicant]
Hernando, et al., “Biochemical and Physical Characterization of Parvovirus Minute Virus of Mice Virus-like Particles”, Virology, vol. 267, No. 2, Feb. 15, 2000, pp. 299-309.
[cited by applicant]
JP2016-539674, “Office Action”, Aug. 27, 2018, 6 pages.
[cited by applicant]
Kajigaya, et al., “Self-Assembled B19 Parvovirus Capsids, Produced in a Baculovirus System, are Antigenically and Immunogenically Similar to Native Virions”, Proceedings of the National Academy of Sciences of the United…
[cited by applicant]
Khan, et al., “Filter Preconditioning Enables Representative Scaled-Down Modelling of Filter Capacity and Viral Clearance by Mitigating the Impact of Virus Spike Impurities”, Biotechnology Applied Biochemistry, vol. 52,…
[cited by applicant]
Kratz, et al., “Native Display of Complete Foreign Protein Domains on The Surface of Hepatitis B Virus Capsids”, Proceedings of the National Academy of Sciences of the United States of America, vol. 96, No. 5, Mar. 2, 1…
[cited by applicant]
Kuck, et al., “Development of AAV Serotype-Specific ELISAs Using Novel Monoclonal Antibodies”, Journal of Virological Methods, vol. 140, Nos. 1-2, Mar. 2007, pp. 17-24.
[cited by applicant]
Kundu, et al., “Evaluation of Viral Clearance in Purification Processes”, Process Scale Bio separations for the Biopharmaceutical Industry, , 2007, pp. 419-448.
[cited by applicant]
Lind, et al., “Development and Evaluation of Three Real-Time Immuno-PCR Assemblages for Quantification of PSA”, Journal of Immunological Methods, vol. 304, Nos. (1-2), Sep. 2005, pp. 107-116.
[cited by applicant]
Livingston, et al., “Serodiagnosis of Mice Minute Virus and Mouse Parvovirus Infections in Mice by Enzyme-linked Immunosorbent Assay With Baculovirus-expressed Recombinant Vp2 Proteins”, Clinical and Vaccine Immunology,…
[cited by applicant]
Lute, et al., “Characterization of Coliphage PR772 and Evaluation of Its Use for Virus Filter Performance Testing”, Applied and Environmental Microbiology, vol. 70, No. 8, Aug. 2004, pp. 4864-4871.
[cited by applicant]
Maerz, et al., “Improved Removal of Viruslike Particles from Purified Monoclonal Antibody IgM Preparation Via Virus Filtration”, Nature Biotechnology, vol. 14, No. 5, May 1996, pp. 651-652.
[cited by applicant]
Mehta, et al., “Detection of Potential Microbial Antigens by Immuno-PCR (PCR-Amplified Immunoassay)”, Journal of Medical Microbiology, vol. 63, No. 5, May 1, 2014, pp. 627-641.
[cited by applicant]
Miesegaes, et al., “Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies”, Biotechnology and Bioengineering, vol. 106, No. 2, Jun. 1, 2010, pp. 238-246.
[cited by applicant]
PCT/IB2014/064352, “International Search Report and Written Opinion”, Mar. 16, 2015, 15 pages.
[cited by applicant]
Peabody, “A Viral Platform for Chemical Modification and Multivalent Display”, Journal of Nanobiotechnology, vol. 1, No. 5, Jul. 2003, pp. 1-8.
[cited by applicant]
Shi, et al., “Real Time Quantitative PCR as a Method to Evaluate Xenotropic Murine Leukemia Virus Removal During Pharmaceutical Protein Purification”, Biotechnology and Bioengineering, vol. 87, No. 7, Sep. 30, 2004, pp.…
[cited by applicant]
Valera, et al., “Application of Multivirus Spike Approach for Viral Clearance Evaluation”, Biotechnology and Bioengineering, vol. 84, No. 6, Dec. 20, 2003, pp. 714-722.
[cited by applicant]
Wang, et al., “Non-Infectious Virus-Like Particles for the Validation of Membrane Integrity and Column Performance in Bioprocessing”, Food and Bioproducts Processing, vol. 98, No. 6, Apr. 2016, pp. 327-332.
[cited by applicant]
Willkommen, et al., “Viral Clearance Integration (Session IV): General Trends, Bracketing, QbD, Virus Preparation Quality Attributes”, PDA Journal of Pharmaceutical Science and Technology, vol. 68, No. 1, Jan.-Feb. 2014…
[cited by applicant]
Wistuba, et al., “Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly”, Journal of Virology, vol. 71, No. 2, Feb. 1997, pp. 1341-1352.
[cited by applicant]
Wobus, et al., “Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infecti…
[cited by applicant]
Yang, et al., “HIV-1 Virus-like Particles Produced by Stably Transfected
[cited by applicant]
Zhang, et al., “A Novel, Q-PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography”, Biotechnology and Bioengineering, vol. 102, No. 5, Apr. 2009, pp. 1438-1447.
[cited by applicant]
Zhao, et al., “Evaluation of Viral Removal by Nanofiltration Using Real-Time Quantitative Polymerase Chain Reaction”, Biotechnology and Applied Biochemistry, vol. 47, No. 2, Jun. 2007, pp. 97-104.
[cited by applicant]
Zoon, et al., “Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use”, U. S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation…
[cited by applicant]
EP14843784.1, “Office Action”, Mar. 23, 2018, 6 pages.
[cited by applicant]
U.S. Appl. No. 14/481,364, “Non-Final Office Action”, Nov. 17, 2014, 12 pages.
[cited by applicant]
AU2021200484, “Notice of Acceptance”, Jun. 16, 2023, 4 pages.
[cited by applicant]
Australian Patent Application No. AU2023229501, “First Examination Report”, Mar. 6, 2025, 3 pages.
[cited by applicant]
Australian Patent Application No. AU2023229501, “Notice of Acceptance”, Mar. 21, 2025, 4 pages.
[cited by applicant]